

# Effects of Vedolizumab Induction Therapy for Patients with Crohn's Disease Who Failed Tumor Necrosis Factor Antagonist Treatment

Gastroenterology

147, 618-627.e3

DOI: [10.1053/j.gastro.2014.05.008](https://doi.org/10.1053/j.gastro.2014.05.008)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Designing biologic selectivity for inflammatory bowel disease &ndash; role of vedolizumab. Drug Design, Development and Therapy, 2015, 9, 147.	2.0	7
4	Risk of Infections of Biological Therapies with Accent on Inflammatory Bowel Disease. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 485.	0.9	17
5	New Drugs on the Horizon for IBD. Digestive Diseases, 2014, 32, 74-81.	0.8	17
7	Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. Immunotherapy, 2014, 6, 963-971.	1.0	35
8	Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?. United European Gastroenterology Journal, 2014, 2, 333-344.	1.6	29
9	T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects. Drugs, 2014, 74, 297-311.	4.9	41
10	Editorial: adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2014, 40, 1249-1249.	1.9	2
11	Vedolizumab. Annals of Pharmacotherapy, 2014, 48, 1629-1635.	0.9	15
12	Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases. Gastroenterology, 2014, 147, 981-989.	0.6	85
13	PRISMA&acircEfficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases. Medicine (United Tj ETQq1 1 0.784314 rgBT/Overlo	0.4	57
15	Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 188-202.	1.9	210
16	Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?. Digestive Diseases, 2015, 33, 95-104.	0.8	0
17	Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab. Journal of Market Access & Health Policy, 2015, 3, 29229.	0.8	13
20	Systematic review and meta&acircanalysis: opportunistic infections and malignancies during treatment with anti&acircntegrin antibodies in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 1227-1236.	1.9	68
21	Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients. Inflammatory Bowel Diseases, 2015, 21, 2879-2885.	0.9	158
22	Randomised clinical trial: vécirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 1170-1181.	1.9	86
23	Strategies that target leukocyte traffic in inflammatory bowel diseases. Current Opinion in Gastroenterology, 2015, 31, 441-448.	1.0	30
24	Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn&Ecircs Disease. Inflammatory Bowel Diseases, 2015, 21, 1695-1708.	0.9	47

#	ARTICLE	IF	CITATIONS
25	Complications of biologics in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 296-302.	1.0	17
26	Characteristics of Patients With Crohn's Disease Initiating Vedolizumab Therapy in Real-World Clinical Practice. <i>American Journal of Gastroenterology</i> , 2015, 110, S773-S774.	0.2	2
27	Patient considerations in the management of ulcerative colitis &ndash; role of vedolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1235.	0.9	2
28	Managing refractory Crohn's disease: challenges and solutions. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 131.	1.0	6
29	Pharmacologic therapy for inflammatory bowel disease refractory to steroids. <i>Clinical and Experimental Gastroenterology</i> , 2015, 8, 257.	1.0	22
30	New pharmaceuticals in inflammatory bowel disease. <i>Przegląd Gastroenterologiczny</i> , 2015, 2, 57-60.	0.3	5
31	Current therapy of pediatric Crohn's disease. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 33.	0.5	24
32	The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 669-675.	0.6	11
33	Next-Generation Therapeutics for IBD. <i>Current Gastroenterology Reports</i> , 2015, 17, 21.	1.1	35
34	Vedolizumab: an $\alpha 4\beta 7$ integrin antagonist for ulcerative colitis and Crohn's disease. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 224-233.	1.1	32
35	Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1271-1278.	0.5	11
36	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1915-1934.	1.0	3
37	Biologics in inflammatory bowel disease: what are the data?. <i>United European Gastroenterology Journal</i> , 2015, 3, 419-428.	1.6	102
39	Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 1737-1738.	0.2	37
40	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. <i>Current Opinion in Pharmacology</i> , 2015, 25, 67-71.	1.7	21
41	Medical Therapy for Crohn's Disease: The Present. , 2015, , 35-48.		0
42	The Toronto Consensus Guidelines for Nonhospitalized Ulcerative Colitis: A Welcome Update but Not the End of the Story. <i>Gastroenterology</i> , 2015, 148, 877-880.	0.6	1
43	Medical Therapy: The Future. , 2015, , 49-63.		0

#	ARTICLE	IF	CITATIONS
44	Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow. <i>Digestive Diseases</i> , 2015, 33, 149-163.	0.8	31
45	An update on medical management on Crohn's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 63-78.	0.9	7
46	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. <i>Gastroenterology</i> , 2015, 148, 344-354.e5.	0.6	226
47	Biomarkers of Inflammation in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1275-1285.e2.	0.6	287
48	Vedolizumab for the treatment of inflammatory bowel diseases. <i>Clinical Investigation</i> , 2015, 5, 247-255.	0.0	3
49	New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 113-120.	0.6	13
51	Introducing Vedolizumab to Clinical Practice: Who, When, and How?. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 356-366.	0.6	53
52	Update on the Medical Management of Crohn's Disease. <i>Current Gastroenterology Reports</i> , 2015, 17, 41.	1.1	8
53	Inflammatory Bowel Disease in Children and Adolescents. <i>JAMA Pediatrics</i> , 2015, 169, 1053.	3.3	480
56	Crohn's Disease. , 2015, , .		5
57	Where are we heading to in pharmacological IBD therapy?. <i>Pharmacological Research</i> , 2015, 100, 220-227.	3.1	36
58	Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1473-1479.	1.0	13
59	Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease. <i>BioDrugs</i> , 2015, 29, 57-67.	2.2	15
60	Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. , 2015, 147, 123-135.		209
61	Treatment of IBD: Where We Are and Where We Are Going. <i>American Journal of Gastroenterology</i> , 2015, 110, 114-126.	0.2	176
62	Biologic Drugs in Crohn's Disease and Ulcerative Colitis: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 55-61.	0.3	13
63	Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. <i>Biologics: Targets and Therapy</i> , 2016, 10, 33.	3.0	8
64	THERAPIES FOR CROHN'S DISEASE: a clinical update. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 206-211.	0.3	9

#	ARTICLE	IF	CITATIONS
65	Recent advances in understanding and managing Crohn's disease. <i>F1000Research</i> , 2016, 5, 2896.	0.8	14
66	Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3685-3698.	2.0	38
67	Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. <i>Archives of Medical Science</i> , 2016, 5, 1088-1096.	0.4	12
68	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1999-2015.	0.9	82
69	Does everyone with inflammatory bowel disease need to be treated with combination therapy?. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 287-293.	1.0	1
70	How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 998-1009.	0.9	18
71	Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. <i>Pharmacotherapy</i> , 2016, 36, 861-869.	1.2	3
72	Sandborn W, Feagan BC, Gasink C, et al (2016) A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-to-severe Crohn's disease patients: Results from IM-UNITI. <i>Gastroenterology AGA abstract 768. Colon and Rectum</i> , 2016, 10, 260-263.	0.0	2
73	Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the Evidence. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 38-44.	0.7	10
75	Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2121-2126.	0.9	90
76	Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2425-2431.	0.9	72
77	Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 966-972.e2.	2.4	25
78	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168
80	Efficacy and Safety Profile of Anti-tumor Necrosis Factor- $\alpha$ Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons. <i>Clinical Therapeutics</i> , 2016, 38, 1342-1358.e6.	1.1	25
82	Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1385-1397.e10.	2.4	303
83	Emerging Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2016, 34, 67-73.	0.8	3
84	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, j176.	0.6	141
85	Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis. <i>Pharmacological Reports</i> , 2016, 68, 1237-1243.	1.5	28

#	ARTICLE	IF	CITATIONS
86	Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016, 34, 1241-1253.	1.7	9
87	Next-Generation Therapeutics for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2016, 18, 51.	1.1	19
88	New molecules in the treatment of inflammatory bowel disease. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2016, 39, 411-423.	0.0	3
89	Ustekinumab for the treatment of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 989-994.	1.4	7
90	Therapeutic innovations in inflammatory bowel diseases. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 49-58.	2.3	16
91	Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1090-1102.	1.9	155
92	Comparable outcomes of the consistent use versus switched use of anti-tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1751-1758.	1.0	6
93	Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2016, 36, 913-923.	1.1	38
94	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1946-1960.	13.9	1,316
95	New and Evolving Immunotherapy in Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2016, 1, 85-95.	0.8	18
96	The Next Wave of Biological Agents for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1737-1743.	0.9	8
97	Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2711-2723.	0.9	14
98	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-to-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016, 111, 1147-1155.	0.2	257
99	Vedolizumab in moderately to severely active ulcerative colitis or Crohn's disease: a guide to its use. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 265-275.	0.3	1
100	An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1437-1444.	0.6	184
101	The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 330-338.	1.4	15
105	Integrin-based therapeutics: biological basis, clinical use and new drugs. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 173-183.	21.5	324
106	Vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 129-135.	1.4	1

#	ARTICLE	IF	CITATIONS
107	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016, 48, 360-370.	0.4	34
108	Emerging therapeutic targets and strategies in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 735-744.	1.4	6
110	Leukocyte Trafficking to the Small Intestine and Colon. <i>Gastroenterology</i> , 2016, 150, 340-354.	0.6	285
111	Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?. <i>Digestive Diseases</i> , 2016, 34, 153-159.	0.8	5
112	The Future of IBD Therapy: Where Are We and Where Should We Go Next?. <i>Digestive Diseases</i> , 2016, 34, 175-179.	0.8	38
113	Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 263-273.	1.9	25
114	Vedolizumab in the treatment of Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 283-290.	1.4	12
115	Actualización del diagnóstico y tratamiento de la enfermedad de Crohn. <i>Medicine</i> , 2016, 12, 217-226.	0.0	0
116	Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e135.	1.3	473
117	Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 402-409.	0.6	88
118	Vedolizumab for the treatment of ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 165-175.	1.4	7
119	The Gut-Liver Axis in Primary Sclerosing Cholangitis. <i>Clinics in Liver Disease</i> , 2016, 20, 1-14.	1.0	39
120	Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 242-250.e2.	2.4	155
121	Optimizing biological therapy in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 37-45.	1.4	14
122	Vedolizumab. <i>Journal of Pharmacy Practice</i> , 2016, 29, 503-515.	0.5	6
123	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
124	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	6.1	630
125	Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. <i>Abdominal Radiology</i> , 2017, 42, 1068-1086.	1.0	17

#	ARTICLE	IF	CITATIONS
126	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterología De México (English Edition)</i> , 2017, 82, 46-84.	0.1	7
127	Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions. <i>Digestive Diseases</i> , 2017, 35, 13-20.	0.8	18
128	An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 878-881.	0.5	83
129	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1021-1042.	1.9	41
130	The $\alpha 4\beta 1$ Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 379-391.	0.9	88
131	Anti-TNF Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 791-797.	0.9	13
132	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
133	Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 3-15.	1.9	97
134	Crohn's disease. <i>Lancet, The</i> , 2017, 389, 1741-1755.	6.3	1,594
135	Diagnosis and management of inflammatory bowel disease in children. <i>BMJ: British Medical Journal</i> , 2017, 357, j2083.	2.4	96
136	Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. <i>Nanomedicine</i> , 2017, 12, 1547-1560.	1.7	11
137	Profoundly Expanded T-cell Clones in the Inflamed and Uninflamed Intestine of Patients With Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 831-839.	0.6	30
138	A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1287-1301.	1.6	121
139	Biological Therapy in Pediatric Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 100-110.	1.1	44
140	Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1258-1266.	0.6	15
141	Bringing the Mucosa to Heal With Vedolizumab in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1030-1031.	0.6	0
142	Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 721-725.	0.9	7
143	Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1210-1217.	0.9	21



#	ARTICLE	IF	CITATIONS
144	Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1230-1237.	0.6	82
145	Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 722-729.	0.6	97
146	Exposure-eficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 921-929.	0.6	130
147	Blocking $\alpha 4\beta 7$ Integrin Through Vedolizumab: Necessary but not Sufficient?. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 903-904.	0.6	9
148	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1590-1596.	1.1	56
150	Novel Targeted Therapies for Inflammatory Bowel Disease. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 127-142.	4.0	142
151	French national consensus clinical guidelines for the management of Crohn's disease. <i>Digestive and Liver Disease</i> , 2017, 49, 368-377.	0.4	19
152	Filgotinib for Crohn's disease- expanding treatment options. <i>Lancet</i> , The, 2017, 389, 228-229.	6.3	4
153	Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterología De México</i> , 2017, 82, 46-84.	0.4	22
154	Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2202-2208.	0.9	31
155	Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	4
156	Ustekinumab en el tratamiento de la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 688-698.	0.2	13
157	Medical management of pediatric inflammatory bowel disease. <i>Seminars in Pediatric Surgery</i> , 2017, 26, 360-366.	0.5	10
158	Inflammatory Bowel Disease Clinical. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 121-154.	1.4	10
159	Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 773-790.	1.4	22
160	The Evolution of Treatment Paradigms in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 661-677.	1.0	7
161	Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 589-601.	1.0	5
162	Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 603-626.	1.0	47

#	ARTICLE	IF	CITATIONS
163	Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 627-644.	1.0	24
164	Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E49.	0.9	20
165	Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1301-1315.	0.9	32
166	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 97-106.	0.9	143
167	Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 404-408.	0.9	84
168	Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease. <i>Pharmacogenomics</i> , 2017, 18, 1095-1114.	0.6	11
169	Fatal ulcerative enteritis of the small intestine in a patient with ulcerative colitis treated with vedolizumab. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 1014-1020.	0.2	4
170	Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. <i>BMJ: British Medical Journal</i> , 2017, 357, j2505.	2.4	105
171	Emerging biologics in inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2017, 52, 141-150.	2.3	67
172	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 3-25.	0.6	1,547
173	Ustekinumab to treat Crohn's disease. <i>Gastroenterologiya Y Hepatologiya (English Edition)</i> , 2017, 40, 688-698.	0.0	4
174	Diagnosis and treatment of Crohn's disease. <i>Journal of the Korean Medical Association</i> , 2017, 60, 484.	0.1	1
175	Systemic Chemokine Levels with Gut-Specific Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1827.	1.8	7
176	Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. <i>Intestinal Research</i> , 2017, 15, 285.	1.0	33
177	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2020.	1.8	53
178	Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 139-146.	0.8	1
179	Inflammatory bowel disease in Bahrain: single-center experience. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 133-145.	1.0	12
180	Second Korean guidelines for the management of Crohn's disease. <i>Intestinal Research</i> , 2017, 15, 38.	1.0	39

#	ARTICLE	IF	CITATIONS
181	Recent Advances in the Medical Treatment of Crohn's Disease. Nihon Daicho Komonbyo Gakkai Zasshi, 2017, 70, 601-610.	0.1	0
182	Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab. Clinical and Experimental Gastroenterology, 2017, Volume 10, 293-301.	1.0	24
184	Autologous Haematopoietic Stem Cell Transplantation (AH SCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. Journal of Crohn's and Colitis, 2018, 12, 476-488.	0.6	43
185	Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis. BMJ Open Gastroenterology, 2018, 5, e000195.	1.1	13
186	What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?. Inflammatory Bowel Diseases, 2018, 24, 953-959.	0.9	23
187	Vedolizumab as a rescue therapy for patients with medically refractory Crohn's disease. Colorectal Disease, 2018, 20, 905-912.	0.7	3
188	Combining Anti-TNF- $\alpha$ and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflammatory Bowel Diseases, 2018, 24, 997-1004.	0.9	44
189	Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?. Inflammatory Bowel Diseases, 2018, 24, 1193-1195.	0.9	2
190	Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor- $\alpha$ Antagonist. Pharmacoeconomics, 2018, 36, 853-865.	1.7	14
191	Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumor necrosis factor. Alimentary Pharmacology and Therapeutics, 2018, 47, 1117-1125.	1.9	13
192	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2018, 16, 129-146.	0.3	64
193	Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 896-905.	1.9	99
194	Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 2419-2429.	1.1	47
195	Vedolizumab for the treatment of Crohn's disease. Expert Review of Clinical Immunology, 2018, 14, 179-189.	1.3	6
197	Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2018, 12, 635-643.	0.6	147
198	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the <sc>OBSERV</sc>-IBD cohort. Alimentary Pharmacology and Therapeutics, 2018, 47, 485-493.	1.9	91
199	High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO). Scandinavian Journal of Gastroenterology, 2018, 53, 158-167.	0.6	25
200	Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. Alimentary Pharmacology and Therapeutics, 2018, 47, 573-580.	1.9	54

#	ARTICLE	IF	CITATIONS
201	Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2168-2171.	1.1	2
202	Gut-selective immuno suppression to treat inflammatory bowel disease. <i>Gastrointestinal Nursing</i> , 2018, 16, 40-47.	0.0	0
203	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	2.4	41
204	ACG Clinical Guideline: Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , 2018, 113, 481-517.	0.2	851
205	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 849-860.	0.9	34
206	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018, 50, 675-681.	0.4	34
207	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 167-177.	0.6	44
208	Vedolizumab in IBD: Lessons From Real-world Experience; A Systematic Review and Pooled Analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 245-257.	0.6	119
209	NAD metabolism fuels human and mouse intestinal inflammation. <i>Gut</i> , 2018, 67, 1813-1823.	6.1	104
210	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 105-119.	0.6	76
211	A comprehensive review and update on Crohn's disease. <i>Disease-a-Month</i> , 2018, 64, 20-57.	0.4	318
212	Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. <i>United European Gastroenterology Journal</i> , 2018, 6, 439-445.	1.6	13
213	Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 387-398.	1.7	5
214	An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 101-111.	0.6	18
215	Treatment of Inflammatory Bowel Disease with Biologics. , 2018, , .		1
216	Anti-integrin Agents in IBD: Efficacy and Risk of Complications. , 2018, , 283-301.		0
217	Novel Agents in Inflammatory Bowel Disease. , 2018, , 303-313.		0
218	Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. <i>World Journal of Gastroenterology</i> , 2018, 24, 2457-2467.	1.4	61

#	ARTICLE	IF	CITATIONS
219	The impact of biological interventions on health-related quality of life in adults with Crohn's disease. The Cochrane Library, 2018, , .	1.5	1
220	Novel treatments for inflammatory bowel disease. Korean Journal of Internal Medicine, 2018, 33, 20-27.	0.7	33
221	Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. GastroenterologÅa Y HepatologÅa (English Edition), 2018, 41, 535-543.	0.0	2
222	Vedolizumab, una opciÃ³n en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biolÃ³gicos. GastroenterologÅa Y HepatologÅa, 2018, 41, 535-543.	0.2	3
223	The role of biologics in the treatment of patients with inflammatory bowel disease. British Journal of Hospital Medicine (London, England: 2005), 2018, 79, 686-693.	0.2	5
224	Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World Journal of Gastroenterology, 2018, 24, 4093-4103.	1.4	37
225	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2018, 48, 839-851.	1.9	71
226	Anti-integrin therapy for inflammatory bowel disease. World Journal of Gastroenterology, 2018, 24, 1868-1880.	1.4	80
227	Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2018, 3, 790-802.	3.7	60
228	Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting. Inflammatory Bowel Diseases, 2018, 24, 2431-2441.	0.9	77
229	Vedolizumab use after failure of TNF-Î± antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterology, 2018, 18, 140.	0.8	37
230	Editorial: paradoxical skin lesions during anti-TNF treatmentâ€”an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 684-685.	1.9	0
231	Cost-effectiveness of ustekinumab in moderate to severe Crohnâ€™s disease in Sweden. Cost Effectiveness and Resource Allocation, 2018, 16, 28.	0.6	4
232	Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, S653-S668.	0.6	56
233	Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Diseaseâ€”A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	0.9	56
234	Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2018, 16, 1937-1946.e8.	2.4	113
235	Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2327-2338.	0.9	50
236	Should we use vedolizumab as mono or combo therapy in ulcerative colitis?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 27-34.	1.0	12

#	ARTICLE	IF	CITATIONS
237	Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2165-2172.	0.9	22
238	Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 905-919.	0.6	20
239	Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877278.	1.4	38
240	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 65-77.	1.9	128
241	Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. <i>Clinical Immunology</i> , 2018, 193, 24-32.	1.4	27
242	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	1.9	12
243	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	3.7	126
244	A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. <i>Digestive and Liver Disease</i> , 2018, 50, 1299-1304.	0.4	44
245	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
246	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 713-722.	1.9	10
247	The state of the art on treatment of Crohn's disease. <i>Journal of Gastroenterology</i> , 2018, 53, 989-998.	2.3	28
248	Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 930-937.	0.6	3
249	Success and safety of high infliximab trough levels in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 940-946.	0.6	38
250	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 623-629.	1.9	4
251	TNF inhibitors exacerbate <i>Mycobacterium paratuberculosis</i> infection in tissue culture: a rationale for poor response of patients with Crohn's disease to current approved therapy. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000216.	1.1	22
252	A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. <i>Drug Safety</i> , 2018, 41, 807-816.	1.4	5
253	Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 735-740.	0.8	10
254	Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-9.	0.7	16

#	ARTICLE	IF	CITATIONS
255	Clinical utility of ustekinumab in Crohn's disease. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 35-47.	1.6	32
256	Efficacy of restarting anti-tumor necrosis factor $\pm$ agents after surgery in patients with Crohn's disease. <i>Intestinal Research</i> , 2018, 16, 75.	1.0	7
257	Biologic therapies in ulcerative colitis: primi inter pares?. <i>Current Drug Targets</i> , 2018, 19, 748-756.	1.0	3
258	Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 215-226.	1.6	100
259	A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. <i>JGH Open</i> , 2018, 2, 223-234.	0.7	30
260	Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. <i>Frontiers in Immunology</i> , 2018, 9, 1700.	2.2	38
261	Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 1048-1064.	2.3	123
262	Treatment Perspectives in Crohn's Disease. <i>Digestion</i> , 2018, 98, 135-142.	1.2	8
263	Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-to-severe Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 394-409.	1.9	146
264	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000208.	1.1	29
265	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 130-138.e7.	2.4	76
266	Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 486-493.	2.4	76
267	Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center. <i>Digestive Diseases</i> , 2019, 37, 33-44.	0.8	12
268	Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 580-586.	0.9	40
269	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 79-96.	0.8	53
270	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	2.4	32
271	Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. <i>Pharmacoeconomics</i> , 2019, 37, 1509-1523.	1.7	7
272	A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 26, 570-580.	0.9	10

#	ARTICLE	IF	CITATIONS
273	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 320-348.	0.6	49
274	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e35-e63.	0.1	16
275	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.1	32
276	Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience. <i>Gastroenterology Report</i> , 2019, 7, 322-330.	0.6	8
277	Efficacy of vedolizumab in granulomatous cheilitis refractory to TNF inhibitors. <i>International Journal of Dermatology</i> , 2019, 58, e236-e237.	0.5	5
278	Medical management of Crohn's disease: state of the art and future perspectives. <i>Italian Journal of Medicine</i> , 2019, 13, 152-160.	0.2	1
279	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. <i>Intestinal Research</i> , 2019, 17, 285-310.	1.0	77
280	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	0.6	86
281	The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 369-379.	0.9	7
282	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1007-1018.e7.	0.6	145
283	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019, 381, 1201-1214.	13.9	703
284	Recent advances in monoclonal antibody therapy in IBD: practical issues. <i>Frontline Gastroenterology</i> , 2019, 10, 409-416.	0.9	27
285	Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 361-366.	1.4	10
286	Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 408-418.	1.9	60
287	Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. <i>Journal of Pediatric Surgery</i> , 2019, 54, 2162-2165.	0.8	15
288	Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2090-2095.	1.4	6
289	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 40-53.	1.9	46
290	Interfering with leukocyte trafficking in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101617.	1.0	18



#	ARTICLE	IF	CITATIONS
291	A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2529.	1.8	78
292	Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. <i>Frontiers in Pharmacology</i> , 2019, 10, 671.	1.6	55
293	Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 741-749.	1.6	17
294	Network meta-analysis to inform positioning of biologics in patients with Crohn's disease: Promise and perils. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101614.	1.0	6
295	Autologous stem cell transplantation in refractory Crohn's disease " low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019, 19, 82.	0.8	17
296	A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. <i>Drugs</i> , 2019, 79, 1053-1063.	4.9	22
297	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1655-1668.e3.	2.4	214
298	Crohn's disease - treatment with biological medication. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 554-567.	0.3	8
299	Biologics and Inflammatory Bowel Disease. <i>GI Surgery Annual</i> , 2019, , 91-119.	0.0	0
300	A product review of vedolizumab in inflammatory bowel disease. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2482-2490.	1.4	20
301	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <i>Immunotherapy</i> , 2019, 11, 565-575.	1.0	2
302	Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. <i>Drug Safety</i> , 2019, 42, 617-632.	1.4	17
303	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 978-996.	1.9	14
304	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1296-1315.	1.4	34
306	Therapeutic Efficacy and Adverse Events of Tacrolimus in Patients with Crohn's Disease: Systematic Review and Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2945-2954.	1.1	4
307	The Role of Early Biologic Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1896-1905.	0.9	124
309	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101602.	1.0	19
310	Treatment sequence network meta-analysis in Crohn's disease: a methodological case study. <i>Current Medical Research and Opinion</i> , 2019, 35, 733-756.	0.9	10

#	ARTICLE	IF	CITATIONS
311	P586 Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn's disease: a multi-centre retrospective cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S407-S408.	0.6	1
312	Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. <i>PLoS ONE</i> , 2019, 14, e0212989.	1.1	59
314	Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice. <i>Biologics</i> , 2019, 58, 50-56.	0.5	2
315	Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1111-1120.	0.6	36
317	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1189-1197.	1.6	31
319	Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2019, 42, 650-656.	0.0	0
320	Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 131-141.	1.0	6
321	A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. <i>Medicine (United States)</i> , 2019, 98, e14681.	0.4	5
322	Positioning biologics and new therapies in the management of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 296-301.	1.0	5
323	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 270-282.	0.9	48
324	Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience. <i>Digestive and Liver Disease</i> , 2019, 51, 68-74.	0.4	24
325	Biological Modifiers of Inflammatory Diseases. , 2019, , 1197-1210.e1.		1
326	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 50-57.	0.6	61
327	TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 70-80.	0.3	67
328	Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1175-1181.	1.4	25
329	25 Ulcerative Colitis. , 2019, , .		0
330	Malt1 inactivation attenuates experimental colitis through the regulation of Th17 and Th1/17 cells. <i>Inflammation Research</i> , 2019, 68, 223-230.	1.6	12
331	A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 820-830.	0.9	76

#	ARTICLE	IF	CITATIONS
332	The Kock Pouch. , 2019, , .		0
333	Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort. Scandinavian Journal of Gastroenterology, 2019, 54, 41-48.	0.6	14
334	Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 319-330.	1.4	37
335	Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3. Inflammatory Bowel Diseases, 2019, 25, 1375-1382.	0.9	14
336	Anti- $\alpha$ 4 $\beta$ 7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2019, 54, 987-993.	1.3	41
337	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 410-420.	0.9	28
338	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clinical Immunology, 2019, 206, 9-14.	1.4	63
339	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 179-187.e6.	2.4	57
340	Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflammatory Bowel Diseases, 2020, 26, 103-111.	0.9	34
341	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti- $\alpha$ 4 $\beta$ 7 integrin therapies. Medicinal Research Reviews, 2020, 40, 245-262.	5.0	60
342	Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. Journal of Crohn's and Colitis, 2020, 14, 542-556.	0.6	50
343	Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. Journal of the Canadian Association of Gastroenterology, 2020, 3, 74-82.	0.1	6
345	The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. Journal of Crohn's and Colitis, 2020, 14, 192-204.	0.6	45
346	Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Journal of Crohn's and Colitis, 2020, 14, 332-341.	0.6	27
347	Anti-MADCAM therapy for ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 437-442.	1.4	9
348	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 2020, 14, 4-22.	0.6	741
349	Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. Journal of Gastroenterology, 2020, 55, 291-306.	2.3	34
350	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opinion on Biological Therapy, 2020, 20, 151-161.	1.4	7

#	ARTICLE	IF	CITATIONS
351	Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 205-213.	1.4	6
352	Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 149-157.	1.9	31
353	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	1.9	30
354	The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 234-242.	0.1	14
355	Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 501-507.	0.9	12
356	Anti-Integrins, Anti-Interleukin 12/23p40, and JAK Inhibitors for the Inflammatory Bowel Disease Treatment. , 0, , .		0
357	Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. <i>Current Opinion in Pharmacology</i> , 2020, 55, 17-30.	1.7	23
358	Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab. <i>Crohn's &amp; Colitis</i> 360, 2020, 2, .	0.5	1
359	The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease. <i>Gastroenterology Report</i> , 2020, 8, 404-406.	0.6	13
360	Current Status of Medical Therapy for Inflammatory Bowel Disease: The Wealth of Medications. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2769-2779.	1.1	12
361	&lt;p&gt;Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 8537-8552.	3.3	10
362	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1236-1245.	0.2	23
363	Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093653.	1.4	13
364	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multicentre study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1045-1055.	1.6	21
365	Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. <i>Current Opinion in Pharmacology</i> , 2020, 54, 51-58.	1.7	6
366	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	1.9	97
367	Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1341-1352.	1.9	46
368	Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 988-993.	0.6	7

#	ARTICLE	IF	CITATIONS
369	Electron microscopic findings can support multiple etiologies of nephrotoxicity in renal tubules. <i>Ultrastructural Pathology</i> , 2020, 44, 481-488.	0.4	4
370	Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 786-794.	0.6	2
371	Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 191-210.	1.9	2
372	Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113224.	1.4	12
373	Network meta-analysis regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. <i>Statistics in Medicine</i> , 2020, 39, 1846-1870.	0.8	3
374	The role of immunosuppressive agents in the management of severe and refractory immune-related adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 201-210.	0.7	15
375	Predicting Response to Vedolizumab in Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 76.	1.2	11
376	Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 2126.	1.0	3
377	Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. <i>BMC Gastroenterology</i> , 2020, 20, 211.	0.8	21
378	Emerging treatments for inflammatory bowel disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062231989929.	1.1	110
379	Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 609-618.	0.7	4
380	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
381	Fragility index: how fragile is the data that support the American College of Gastroenterology guidelines for the management of Crohn's disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 193-198.	0.8	13
382	Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. <i>Journal of Clinical Medicine</i> , 2020, 9, 385.	1.0	5
383	The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumor necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 948-957.	1.9	84
384	Serum Biomarkers for Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 123.	1.2	104
385	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 662-668.	0.9	18
386	No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 668-679.e8.	2.4	42

#	ARTICLE	IF	CITATIONS
387	Real-world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan. <i>Advances in Digestive Medicine</i> , 2021, 8, 40-46.	0.1	7
388	Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 195-202.	0.6	10
389	The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 171-194.	0.6	265
390	Prevention and Treatment of Strictureing Crohn's Disease – Perspectives and Challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 401-411.	1.4	17
391	Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. <i>AAPS Journal</i> , 2021, 23, 3.	2.2	10
392	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 462-470.	0.6	16
393	Chronisch-entzündliche Darmerkrankungen (CED). , 2021, , 301-336.		0
394	Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	1.4	17
395	Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021, 86, 70-85.	0.1	0
397	Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2020, 11, 585732.	1.6	4
398	Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1931-1941.	0.9	6
399	The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110247.	1.4	9
400	Vedolizumab-Related Arthralgias in Patients with Inflammatory Bowel Disease: A Systematic Review. , 2021, 05, .		0
401	Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612830.	1.8	36
402	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 853.	1.0	22
403	Medical and Endoscopic Management of Crohn Disease. <i>Topics in Magnetic Resonance Imaging</i> , 2021, 30, 43-61.	0.7	0
404	Progress in research of vedolizumab in treatment of inflammatory bowel disease. <i>World Chinese Journal of Digestology</i> , 2021, 29, 248-255.	0.0	1
405	Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. <i>Health Technology Assessment</i> , 2021, 25, 1-138.	1.3	2

#	ARTICLE	IF	CITATIONS
406	Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 1242.	1.0	17
407	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1649-1657.	0.6	10
408	Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1289-1299.	1.9	30
409	Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 655865.	1.6	7
410	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1579-1587.e2.	2.4	22
411	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1986-1998.	0.9	4
412	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 489-526.	2.3	202
413	Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease – a real-world two-center cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e709-e718.	0.8	11
414	Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China. <i>Advances in Therapy</i> , 2021, 38, 4233-4245.	1.3	5
415	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 689-699.	0.9	9
416	Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study. <i>Crohn's &amp; Colitis 360</i> , 2021, 3, .	0.5	5
417	Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, 352-357.	0.9	4
418	AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, 2512-2556.e9.	0.6	44
419	Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2021, 10, 2997.	1.0	13
420	Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 251-257.	0.7	2
421	Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1174-1181.	1.0	9
422	Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study. <i>Digestion</i> , 2021, 102, 929-937.	1.2	3
423	Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice. <i>Cells</i> , 2021, 10, 1847.	1.8	24

#	ARTICLE	IF	CITATIONS
424	Vedolizumab (Entyvio) in Crohn's disease. <i>Gastrointestinal Nursing</i> , 2021, 19, 20-26.	0.0	0
425	Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 1040-1048.	0.6	12
426	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 27-38.	0.6	66
427	Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. <i>Biologics</i> , 2021, 1, 189-210.	2.3	5
428	Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. <i>Gut and Liver</i> , 2022, 16, 157-170.	1.4	8
429	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2014-2025.	0.2	93
430	Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 679258.	1.2	3
431	Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. <i>Frontiers in Medicine</i> , 2021, 8, 737256.	1.2	7
432	Low immunogenicity of vedolizumab determined by a simple drug-tolerant assay in patients with ulcerative colitis. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2022, 70, 72-78.	0.6	2
433	Vedolizumab in Inflammatory Bowel Disease: West versus East. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 1-17.	0.8	1
434	Concepts in Inflammatory Bowel Disease Management. , 2019, , 1888-1918.		1
435	Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 8-16.	0.7	7
436	AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1191-1199.	0.6	14
437	Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 70, 304-309.	0.9	15
438	Biologic therapies for Crohn's disease: optimising the old and maximising the new. <i>F1000Research</i> , 2019, 8, 1210.	0.8	25
439	Circulating exosomes express $\alpha 4 \beta 7$ integrin and compete with CD4+ T cells for the binding to Vedolizumab. <i>PLoS ONE</i> , 2020, 15, e0242342.	1.1	8
440	Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?. <i>Current Pharmaceutical Design</i> , 2019, 25, 19-24.	0.9	2
441	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. <i>Current Drug Metabolism</i> , 2020, 21, 247-255.	0.7	4



#	ARTICLE	IF	CITATIONS
442	Are Surgical Rates Decreasing in the Biological Era In IBD?. <i>Current Drug Targets</i> , 2019, 20, 1356-1362.	1.0	18
443	Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. <i>Journal of Health Economics and Outcomes Research</i> , 2018, 6, 96-112.	0.6	12
444	Integrin antagonists are effective and safe for Crohn's disease: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2015, 21, 4744-4749.	1.4	7
445	Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?. <i>World Journal of Gastroenterology</i> , 2017, 23, 6385-6402.	1.4	51
446	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. <i>World Journal of Gastroenterology</i> , 2020, 26, 6710-6769.	1.4	12
447	Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. <i>World Journal of Hepatology</i> , 2015, 7, 2716.	0.8	7
448	Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2019, 13, 604-616.	1.4	90
449	Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI). <i>Intestinal Research</i> , 2021, 19, 386-397.	1.0	16
450	Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. <i>Drugs in Context</i> , 2020, 9, 1-15.	1.0	12
451	Biologics Targeting in the Treatment of Inflammatory Bowel Disease: A Conundrum. <i>Cureus</i> , 2020, 12, e10621.	0.2	2
452	Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. <i>BioDrugs</i> , 2021, 35, 473-503.	2.2	4
453	Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1002-1014.	3.7	114
455	THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 3-4.	0.3	1
456	New Non-anti-TNF- $\alpha$ Biological Therapies for the Treatment of Inflammatory Bowel Disease. , 2017, , 425-450.		0
457	Chronisch-entzündliche Darmerkrankungen (CED). , 2018, , 247-277.		0
458	Conventional and biological therapy for inflammatory bowel disease. <i>Vnitri Lekarstvi</i> , 2018, 64, 642-653.	0.1	1
459	ORGANIZATIONAL APPROACHES TO DIAGNOSTICS AND TREATMENT OF PATIENTS WITH INFLAMMATORY INTESTINAL DISEASES. <i>Kuban Scientific Medical Bulletin</i> , 2018, 25, 56-60.	0.1	0
460	Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?. <i>Meditinskiy Sovet</i> , 2018, , 44-49.	0.1	0

#	ARTICLE	IF	CITATIONS
461	Vedolizumab, its pharmacological profile and therapeutic use. <i>Klinicka Farmakologie A Farmacie</i> , 2018, 32, 11-14.	0.1	0
462	Management of de Novo Crohn's Disease after Reconstructive Surgery with Continent Ileostomy in Ulcerative Colitis. , 2019, , 143-165.		0
463	Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow. <i>Russian Journal of Evidence-Based Gastroenterology</i> , 2019, 8, 55.	0.3	0
464	Integrin inhibitors: natalizumab and vedolizumab. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2019, 30, 603-609.	0.1	0
465	Preguntas y respuestas sobre el manejo de la enfermedad de Crohn y la colitis ulcerosa con vedolizumab. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 650-656.	0.2	0
467	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 280-290.	2.2	4
468	Les nouveaux traitements des maladies inflammatoires chroniques de l'intestin. <i>La Presse Médicale Formation</i> , 2020, 1, 25-32.	0.1	0
469	What to Do When Biologic Agents Are Not Working in Inflammatory Bowel Disease Patients. <i>Gastroenterology and Hepatology</i> , 2015, 11, 657-65.	0.2	10
470	A SPECIAL MEETING REVIEW EDITION: CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn's Disease: A Review of Selected Presentations From the CCFA/Advances in Inflammatory Bowel Diseases 2015 Clinical and Research Conference December 10-12, 2015 Orlando, Florida Special Reporting on: New and Future Adhesion Molecule-Based Therapies in IBD Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice A Multicenter, Double-Blind, Placebo-	0.2	2
471	Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2016, 12, 1-20.	0.2	2
472	Use of Vedolizumab for the Treatment of Crohn's Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 204-206.	0.2	2
473	Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 656-665.	0.2	15
474	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 265-272.	1.9	3
475	Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2020, 16, 400-414.	0.2	1
476	Rare Complication During Anti-TNF Treatment in a Patient with Crohn's Disease: A Case Report and Review of the Literature. <i>Current Health Sciences Journal</i> , 2021, 47, 132-138.	0.2	0
477	Crohn's Disease. , 2022, , 379-391.		0
478	A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 746-756.	0.6	18
479	Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5551.	1.0	9

#	ARTICLE	IF	CITATIONS
480	Medical Therapy for Crohn's Disease. , 2022, , 781-798.		0
481	Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF) Tj ETQq1 1 0.784314 rgBT /Overlook	1.0	28
482	Vedolizumab: An Emerging Treatment Option for Pediatric Inflammatory Bowel Disease. Journal of Pediatric Pharmacology and Therapeutics, 2021, 26, 795-801.	0.3	3
483	An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease. European Medical Journal Gastroenterology, 0, , 91-101.	0.0	0
484	Biologic agents and small molecules " mechanism of action. Seminars in Colon and Rectal Surgery, 2022, , 100861.	0.2	0
485	Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2022, , 1.	1.1	0
487	A review of the therapeutic management of Crohn's disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210784.	1.4	13
488	Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis: preliminary phase IB/IIA study. British Journal of Surgery, 2022, 109, 653-655.	0.1	3
489	Current treatment modalities in granulomatous cheilitis. International Journal of Dermatology, 2022, 61, 755-759.	0.5	6
490	Natural compounds as safe therapeutic options for ulcerative colitis. Inflammopharmacology, 2022, 30, 397-434.	1.9	26
491	Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn's Disease. Frontiers in Immunology, 2022, 13, 828219.	2.2	4
493	Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study. Journal of Crohn's and Colitis, 2022, 16, 1243-1254.	0.6	18
494	MAdCAM-1 Costimulates T Cells through Integrin $\alpha 4 \beta 7$ to Cause Gene Expression Events Resembling Costimulation through CD28. ImmunoHorizons, 2022, 6, 211-223.	0.8	4
495	Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterology, 2022, 13, 490-496.	0.9	2
496	Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatrics, 2022, 22, 175.	0.7	6
497	Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis, 2022, 16, 852-862.	0.6	7
498	Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease " a systematic review with meta-analysis. Digestive and Liver Disease, 2022, 54, 1168-1178.	0.4	17
499	Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Alimentary Pharmacology and Therapeutics, 2021, 53, 265-272.	1.9	13

#	ARTICLE	IF	CITATIONS
500	Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210858.	1.4	4
511	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. <i>Gut</i> , 2022, 71, 1781-1789.	6.1	11
513	Update on the Use of Vedolizumab in Patients With Crohn's Disease.. <i>Gastroenterology and Hepatology</i> , 2021, 17, 491-493.	0.2	0
514	Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100104.	1.7	15
515	Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>SSRN Electronic Journal</i> , 0, .	0.4	0
516	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 463-476.	1.9	12
517	Is it time to include older adults in inflammatory bowel disease trials? A call for action. <i>The Lancet Healthy Longevity</i> , 2022, 3, e356-e366.	2.0	14
518	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <sc>IG&IBD LIVE</sc> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
519	Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis. <i>ACG Case Reports Journal</i> , 2022, 9, e00788.	0.2	4
520	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	15
521	A phase <sc>IB</sc>/<sc>IIA</sc> study of <sc>remestemcel&lt;/sc>, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. <i>Colorectal Disease</i> , 2022, 24, 1358-1370.	0.7	5
522	Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 2051-2059.	1.4	6
523	Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience. , 2022, 33, 831-837.		0
524	Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review. <i>Crohn's &amp; Colitis 360</i> , 2022, 4, .	0.5	1
525	Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8137.	1.8	9
526	Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
527	Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. <i>Gut</i> , 2023, 72, 264-274.	6.1	48
528	Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 906-919.	0.7	1

#	ARTICLE	IF	CITATIONS
529	Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1800-1812.	0.9	9
530	Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 1015-1023.	0.9	3
531	Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis. <i>Medicina Oral, Patología Oral Y Cirugía Bucal</i> , 2022, , e588-e599.	0.7	1
532	Biologics: how far can they go in Crohn's disease?. <i>Gastroenterology Report</i> , 2022, 10, .	0.6	9
533	Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
534	The therapeutic effects of cycloastragenol in ulcerative colitis by modulating SphK/MIP1 $\beta$ /miR-143 signalling. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 131, 406-419.	1.2	8
535	Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 199-210.	0.6	2
536	Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 31-42.	3.7	16
537	Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. <i>Medicine (United States)</i> , 2022, 101, e30590.	0.4	5
538	Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. <i>Intestinal Research</i> , 2023, 21, 43-60.	1.0	11
539	Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease. <i>Digestion</i> , 2023, 104, 30-41.	1.2	20
540	$\alpha$ 4-Integrin (and Other Leukocyte Integrin)-Targeting Agents. , 2022, , 253-272.		0
541	Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn's & Colitis 360. <i>Crohn's &amp; Colitis 360</i> , 2022, 4, .	0.5	3
542	Vedolizumab: what is the benefit from increasing the dose frequency?. <i>Drug and Therapeutics Bulletin</i> , 0, , dtb-2022-000012.	0.3	0
543	Successful long-term treatment of paediatric ulcerative colitis with vedolizumab: a case report. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, e30-e30.	0.5	1
544	Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	6
545	Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease" a systematic review with meta-analysis. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0
546	An update on efficacy and safety comparison of biologics in treatment of inflammatory bowel disease targeting TNF $\alpha$ , interleukins, leukocyte trafficking, Janus-kinase, and sphingosine-1-phosphate receptor. <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-25.	1.4	1

#	ARTICLE	IF	CITATIONS
547	Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0
548	The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
549	Multicenter Study of Non-adherence to Self-Injectable Biologic Therapy in Patients with IBD: Risk Factors and Outcomes. , 2023, , .		0
550	In It for the Long Haul: Managing the Complexity of Crohn's Disease. <i>European Medical Journal Gastroenterology</i> , 0, , 2-11.	0.0	0
551	Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease. <i>Journal of Health Economics and Outcomes Research</i> , 0, , 96-112.	0.6	0
552	Conventional treatment and new drugs. , 2023, , 47-69.		0
553	Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review. <i>Biomedicines</i> , 2023, 11, 544.	1.4	4
554	New Non-anti-TNF- $\alpha$ Biological Therapies for the Treatment of Inflammatory Bowel Disease. , 2023, , 457-493.		0
555	Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2023, 11, 202-217.	1.6	7
556	Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. <i>Journal of Crohn's and Colitis</i> , 2023, 17, 1217-1227.	0.6	6
557	Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2023, , .	0.4	3
558	Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
559	Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 2503.	1.0	1
560	Is there an optimal sequence of biologic therapies for inflammatory bowel disease?. <i>Therapeutic Advances in Gastroenterology</i> , 2023, 16, 175628482311594.	1.4	7
561	Biologic Response Modifiers. , 2023, , 1089-1101.		0
562	Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy. <i>Cancers</i> , 2023, 15, 2389.	1.7	6
601	Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2024, 47, 333-354.	1.4	1